At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 704 enrolled
Drug / intervention
Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine (Menveo)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3b, Controlled, Open-Label, Multi-Center Study to Evaluate Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's Meningococcal ACWY Conjugate Vaccine (Menveo), Administered to Healthy Individuals 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination
In Brief
A Phase 3 clinical trial evaluating Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine (Menveo) for Infections, Meningococcal. Completed, enrolled 704 participants across 37 sites in 2 countries.
Detailed Summary
The purpose/aim of this study is to assess the safety and antibody response to vaccination with a booster dose of Menveo given 4-6 years after primary MenACWY vaccination and to assess the safety and antibody response to a single dose of Menveo given to vaccine-naïve subjects
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfections, Meningococcal
CountriesPuerto Rico, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedDec 2016
Enrollment StartDec 2016
Primary CompletionJul 2017
Study CompletionDec 2017
TodayJul 2026
First PostedDec 8, 2016
Enrollment StartDec 8, 2016
Primary CompletionJul 17, 2017
Study CompletionDec 7, 2017
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 9.6 years ago
Interventions
Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine (Menveo)biological
One intramuscular injection of MenACWY at Day 1.